Cancer Pain - Pipeline Review, H2 2020
- $ 2000
- May 2024
- 154 pages
PAX-## is under development for the treatment of cancer pain, inflammatory pain, neuropathic pain, newly diagnosed glioblastoma and recurrent glioblastoma and non-small cell lung carcinoma, lymph non-small cell lung carcinoma, metastatic breast cancer, metastatic soft-tissue cancer, metastatic osteosarcoma, metastatic gastric cancer, metastatic renal cancer, metastatic ovarian cancer, metastatic bladder cancer, metastatic cervical cancer, metastatic endometrial cancer, metastatic head and neck cancer, metastatic prostate cancer, malignant melanoma, cholangiocarcinoma, prostate cancer and multiple myeloma, brain cancer and coronavirus disease 2019 (COVID-##). [...] It is in Phase I stage of development for the treatment of non-small cell lung carcinoma, lymph non-small cell lung carcinoma, metastatic breast cancer, metastatic soft-tissue cancer, metastatic osteosarcoma, metastatic gastric cancer, metastatic renal cancer, metastatic ovarian cancer, metastatic bladder cancer, metastatic cervical cancer, metastatic endometrial cancer, cholangiocarcinoma, malignant melanoma, metastatic head and neck cancer in US. It is in Phase II stage of development for the treatment of metastatic prostate cancer and in Phase I stage of development for multiple myeloma.